<DOC>
	<DOCNO>NCT01320020</DOCNO>
	<brief_summary>The study design open-label dose-escalation study investigate safety tolerability catumaxomab qwk patient epithelial cancer . The treatment period dose escalation ( dose limit toxicity ( DLT ) period ) consist 4 week , comprise 4 single i.v . administration catumaxomab follow 1 week safety observation administration . All patient offer continuation catumaxomab treatment dose disease progression death , whichever occur first .</brief_summary>
	<brief_title>A Open Label , Dose Escalating Study Evaluate Safety Tolerability Ascending Intravenous ( i.v . ) Doses Catumaxomab Epithelial Cancer Patients</brief_title>
	<detailed_description>Epithelial cancer patient progress standard therapy standard therapy exist . Catumaxomab ( trifunctional anti-EpCAM x anti-CD3 antibody ) Catumaxomab administer i.v . weekly ( qwk ) infusion last 6 hour . The start dose catumaxomab 2 µg . The dose escalation schedule base Modified Fibonacci Schedule follow dose cohort : 2 µg , 4 µg , 7 µg , 10 µg , 14 µg 19 µg qwk correspond dose increment 100 % , 75 % , 43 % , 40 % 36 % respectively previous dose . Subsequent dose level correspond dose increment 30 % , e.g . 25 , 33 , 43 , 56 µg . After completion DLT period , patient offer continuation catumaxomab treatment dose disease progression death , whichever occur first . The maximum length treatment , however , restrict additional 12 week DLT period - result maximum treatment duration 16 week total .</detailed_description>
	<mesh_term>Antibodies , Bispecific</mesh_term>
	<criteria>1 . Patients epithelial cancer know EpCAM overexpression least 80 % patient , progress standard therapy standard therapy exist . 2 . At least one assessable lesion accord RECIST least one dimension compute tomography ( CT ) . 3 . Life expectancy ≥ 3 month . 4 . Age ≥ 18 year . 5 . ECOG Performance Status ≤ 1 6 . Females childbearing potential must negative serum pregnancy test within 48 hour prior first infusion catumaxomab must use effective contraception ( intrauterine device , hormonal contraceptive , contraceptive pill , implant , transdermal patch , hormonal vaginal device , injection prolong release ) study least 13 day participate study . 7 . Patients capable understand purpose risk study , willing able participate study write date informed consent participate study obtain . 1 . Patients know clinically symptomatic brain metastasis . 2 . Concomitant cancer chemo radiotherapy ( except local radiation therapy bone marrow metastasis ) 3 . Treatment investigational product within 4 week prior first administration catumaxomab 4 . In case previous exposure cancer , chemo , immune radiotherapy ( except local radiation therapy bone marrow metastasis ) patient must exclude sufficiently recover previous treatment ( toxicity present ) base adequate laboratory value general status accord in/exclusion criterion ( i.e . might less 1 2 week weekly biweekly schedule previous therapy regimen ) . 5 . Exposure nitrosoureas mitomycin C within 6 week prior first infusion catumaxomab . 6 . Abnormal organ bone marrow function define ( single parameter fulfill condition ) : 6.1 . ANC &lt; 1.5 ( 1.5x109/L , 1500/mm3 ) 6.2 . Hemoglobin &lt; 9.0 g/dL 6.3 . Platelet count &lt; 75 ( 75x109/L , 75,000/mm³ ) 6.4 . AST ( SGOT ) /ALT ( SGPT ) &gt; 3 x upper limit normal ( ULN ) ; 6.5 . Alkaline phosphatase &gt; 2.5 x ULN 6.6 . Serum ( total ) bilirubin &gt; 1.5 x ULN ; 6.7 . Serum creatinine &gt; 1.5 x ULN ; 6.8 . Serum creatinine &gt; 1.5 x ULN ( exception : pt anticoagulant therapy ) 7 . Use immunesuppressive agent past 4 week prior first administration catumaxomab . For regular use systemic corticosteroid , patient include stepwise discontinuation free steroid minimum 5 day prior first administration catumaxomab . 8 . Any known active chronic infection . 9 . Known infection human immunodeficiency virus ( HIV positive ) and/or hepatitis B virus ( HBsAg positive ) hepatitis C virus ( antiHCV positive ) . 10 . Any concurrent disease medical condition deem interfere conduct study judge investigator . 11 . Known hypersensitivity catumaxomab analogues general , component study drug formulation . 12 . Patients congestive heart failure NYHA Class III IV . Cardiac arrhythmia ( except atrioventricular block type I II , atrial fibrillation/flutter , bundle brunch block ) sign symptom relevant cardiovascular disease . 13 . Pregnant woman , nurse mother , lactate woman , woman childbearing potential unwilling use effective contraception ( intrauterine device , hormonal contraceptive , contraceptive pill , implant , transdermal patch , hormonal vaginal device , injection prolong release ) . Effective contraception must use duration study least 13 day participate study . Effective contraception must use men woman duration study least 13 day participate study . 14 . Unwilling unable follow protocol requirement . 15 . Patients history liver cirrhosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Neoplasm</keyword>
	<keyword>Carcinoma</keyword>
	<keyword>intravenous</keyword>
	<keyword>Monoclonal Antibody</keyword>
	<keyword>Removab</keyword>
</DOC>